KRAS-mutant lung adenocarcinomas associated with KEAP1 mutational inactivation demonstrated lower expression rates of PD-L1 and other immune markers, proving refractory to anti–PD-1 antibody therapy [51,52]. The gene discussed is KRAS; the disease is lung adenocarcinoma.